Retatrutide: Side Effects & Safety

Retatrutide (LY3437943) is Eli Lilly's investigational once-weekly triple agonist of GLP-1, GIP, and glucagon receptors. Its safety profile is characterized primarily by two landmark Phase 2 trials published in 2023: a 338-patient obesity trial in The New England Journal of Medicine^[1] and a 281-patient type 2 diabetes trial in The Lancet.^[2] Both followed patients for 48 weeks. Phase 3 obesity (TRIUMPH program) and Phase 3 cardiovascular outcomes trials are ongoing as of 2026 and have not yet reported.

Retatrutide is not yet FDA-approved and is not legally available as a finished drug product. It is not on the agenda for the July 2026 FDA Pharmacy Compounding Advisory Committee meeting (the seven peptides under review are BPC-157, TB-500, KPV, MOTS-c, Emideltide/DSIP, Epitalon, and Semax). The retatrutide circulating in research-peptide markets is unregulated and not the clinical-grade molecule used in Lilly trials. See our legal status guide for the broader regulatory picture.

Frequencies below are pooled across active dose groups (1 mg, 4 mg, 8 mg, 12 mg weekly) in the 48-week obesity trial.^[1]

Effect	Frequency (active arms)	Severity	Notes
Nausea	26–45%	Mostly mild–moderate	Peaks during dose titration; resolves with stable dosing
Diarrhea	15–22%	Mild–moderate, transient	Usually self-resolves within 1–2 weeks
Vomiting	8–18%	Dose-dependent	More common at 8–12 mg doses
Decreased appetite	10–15%	Pharmacological effect, not adverse	Mechanism of action, not a side effect per se
Constipation	8–12%	Mild	From slowed gastric motility
Increased heart rate	Mean +5–7 bpm	Generally well tolerated	Notable class signal vs semaglutide/tirzepatide which see +2–4 bpm
Injection-site reactions	5–10%	Mild, transient	Standard SC injection profile
Discontinuation due to adverse events	5–10% (dose dependent)	—	Most discontinuations were GI-related

No retatrutide-related deaths were reported in Phase 2. The serious adverse event rate did not significantly exceed placebo. Mean weight loss in the highest dose group (12 mg) was 24.2% at 48 weeks — the largest pharmacologic weight loss reported to date.^[1]

The most distinctive safety signal in retatrutide Phase 2 data is a higher mean increase in resting heart rate (~5–7 bpm) than seen with semaglutide (Wegovy ~2 bpm) or tirzepatide (Mounjaro/Zepbound ~3 bpm). The mechanism likely relates to the glucagon receptor component (which retatrutide adds versus the GLP-1/GIP combination of tirzepatide and pure GLP-1 of semaglutide).

Why this matters: long-term cardiovascular safety in a population with substantial baseline cardiovascular risk has not yet been demonstrated. The ongoing Phase 3 cardiovascular outcomes trial will provide the definitive data. Until then, anyone with a history of arrhythmia, structural heart disease, or uncontrolled hypertension should not initiate retatrutide outside a clinical trial.

Retatrutide shares the safety class warnings of FDA-approved GLP-1 / GIP agonists (semaglutide, tirzepatide, liraglutide):

• Acute pancreatitis: reported with all GLP-1 agonists at low absolute rates. Discontinue with persistent severe abdominal pain.
• Thyroid C-cell tumors: rodent C-cell hyperplasia and medullary thyroid carcinoma seen in GLP-1 toxicology studies. FDA-approved drugs in this class carry a boxed warning. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Gallbladder disease: increased gallstones and cholecystitis seen across class; rapid weight loss compounds the risk.
• Acute kidney injury: typically secondary to severe nausea/vomiting/dehydration. Volume status matters.
• Hypoglycemia: uncommon with GLP-1 monotherapy in non-diabetics. Risk rises sharply when combined with insulin or sulfonylureas in diabetic patients.
• Diabetic retinopathy progression: documented signal with rapid HbA1c reduction in semaglutide (SUSTAIN-6); plausible for retatrutide. Pre-existing proliferative retinopathy warrants ophthalmology consultation before initiation.
• Gastroparesis: emerging post-marketing signal in semaglutide and tirzepatide; should be assumed for retatrutide given mechanism.

• Personal or family history of medullary thyroid carcinoma or MEN 2: absolute contraindication for all GLP-1 class drugs.
• Pregnancy: animal data shows reproductive toxicity. Discontinue at least 2 months before planned conception. Not approved during pregnancy.
• Breastfeeding: excretion into human milk unknown. Standard advice is to avoid.
• Severe gastrointestinal disease (gastroparesis, IBD active flare, recurrent pancreatitis): avoid.
• Type 1 diabetes: not studied. Not for use as primary glucose management.
• Severe hepatic or renal impairment: pharmacokinetics not characterized.
• Active malignancy: discuss with oncology.

Drug interactions

• Insulin or sulfonylureas: reduce dose to avoid hypoglycemia.
• Oral medications: delayed gastric emptying may alter absorption — clinically significant for oral contraceptives, levothyroxine, narrow-therapeutic-index drugs. Time dosing accordingly and monitor.
• Warfarin: monitor INR more closely during dose changes.

• Mild nausea / GI symptoms during titration: slow the titration schedule, eat smaller meals, avoid high-fat foods, hydrate aggressively. Most resolves within 1–2 weeks of stable dosing.
• Persistent severe abdominal pain: stop immediately and seek evaluation for pancreatitis (lipase, imaging).
• New onset palpitations, exercise intolerance, or syncope: stop and seek cardiac evaluation.
• Persistent vomiting / dehydration: hold doses, restore volume, evaluate for gastroparesis or other GI pathology.
• Right upper quadrant pain, jaundice: evaluate for gallbladder disease.
• Vision changes (diabetic patients): immediate ophthalmology evaluation for retinopathy progression.

See the retatrutide complete guide, dosage protocols, retatrutide vs tirzepatide, and retatrutide vs semaglutide.